BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

In a significant development for the biotechnology sector, BioNexus Gene Lab Corp. (Nasdaq: BGLC) has successfully regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. This achievement, announced on April 30, 2025, marks a pivotal moment for the Kuala Lumpur-based company, reinforcing its position as a compliant and growth-oriented public entity.

BioNexus Gene Lab Corp., known for its pioneering work in genome screening, specializes in developing non-invasive liquid biopsy tests for early disease risk detection. These tests, derived from rigorous research, aim to reduce treatment costs and optimize patient management based on current health status. The company’s innovative approach serves a global customer base, underscoring its commitment to advancing healthcare solutions.

The company’s recent compliance milestone is a testament to its strategic focus and operational resilience. Under the leadership of CEO Sam Tan, BioNexus has enhanced its corporate governance by appointing new independent board members and establishing an internal audit function. These steps are part of a broader strategy to ensure long-term stability and growth.

BioNexus Gene Lab Corp. operates through two primary divisions: MRNA Scientific and Chemrex. MRNA Scientific is dedicated to expanding RNA-based genomic diagnostics and non-invasive blood tests for 11 major diseases. Meanwhile, Chemrex focuses on scaling specialty materials operations in Southeast Asia, with an emphasis on sustainable development.

The company’s recent financial performance reflects its ongoing efforts to stabilize and grow. As of April 27, 2025, BioNexus Gene Lab Corp. closed at $2.71 per share, a significant recovery from its 52-week low of $2.0068 on April 9, 2025. This rebound highlights the company’s resilience in navigating market challenges.

The official notification from Nasdaq confirming the company’s compliance with Listing Rule 5550(a)(2) is more than just a regulatory achievement. It signals BioNexus Gene Lab Corp.’s readiness to pursue its bold innovation roadmap, engage with capital markets, and expand internationally. This milestone paves the way for the company to continue its mission of transforming healthcare through precision diagnostics and specialty chemical solutions.

As BioNexus Gene Lab Corp. moves forward, its regained compliance serves as a foundation for future growth and innovation. The company’s strategic initiatives, coupled with its commitment to corporate governance and sustainable development, position it well to capitalize on emerging opportunities in the biotechnology sector.

For more information about BioNexus Gene Lab Corp. and its innovative solutions, visit the official website at www.bionexusgenelab.com .